HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $9 price target.
Stocks · News reference
LifeMD Lowers FY2026 Sales Guidance from $220.000M-$230.000M to $205.500M-$212.500M vs $222.046M Est
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $220.000 million-$230.000 million to $205.500 million-$212.500 million vs $222.046 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $8.